ICOTYDE
Live / Applied — First extension granted (statement of use) (as of 05 Nov 2025)
What this means for you
Not registered yet, but its 07 Jan 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98941384
- Mark type
- Stylized text
- Filed
- 07 Jan 2025
- Published for opposition
- 08 Apr 2025
- Attorney of record
- Cheryl Foytlin
Goods and services
- Class 005 — Pharmaceuticals: Human pharmaceutical preparations for the prevention and treatment of auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prosecution history
- 06 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Nov 2025 — SOU EXTENSION 1 GRANTED
- 05 Nov 2025 — SOU EXTENSION 1 FILED
- 05 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 18 Jul 2025 — ASSIGNED TO EXAMINER
- 03 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Apr 2025 — PUBLISHED FOR OPPOSITION
- 02 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 13 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Mar 2025 — ASSIGNED TO EXAMINER
- 07 Jan 2025 — APPLICATION FILING RECEIPT MAILED
- 07 Jan 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 07 Jan 2025 — NEW APPLICATION ENTERED